Moderna
Search results
Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. MAKING A MEANINGFUL IMPACT FOR PEOPLE LIVING WITH RARE DISEASES, EVERYDAY
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Jul 21, 2021 · AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.
Alexion Pharmaceuticals, Inc. | 361,529 followers on LinkedIn. Rare inspiration. Changing lives. | Alexion, AstraZeneca Rare Disease was created following the 2021 acquisition of Alexion ...
At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve.
To date, we have six innovative medicines approved for the treatment of seven rare diseases and devastating conditions. Learn more about each of our medicines and the conditions they treat by selecting a product below.
Dec 12, 2020 · AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
BOSTON -- (BUSINESS WIRE)--May 11, 2021-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting of shareholders held today.
Jul 28, 2023 · Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies. Agreement furthers Alexion’s ambition to transform patient outcomes with genomic medicine and provides synergistic opportunities across AstraZeneca.
Oct 3, 2022 · Alexion, AstraZeneca Rare Disease, today announced that it has entered a definitive agreement to acquire Lexington, Mass.-based LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.
